VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Acalabrutinib monotherapy in R/R MCL: extended follow-up results

Michael Wang, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the follow-up results of a Phase II study (NCT02213926) aiming to assess the efficacy and safety of acalabrutinib monotherapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients. After a median follow-up of 38 months, the overall response rate was 81%, with 48% of the participants achieving a complete response. This long-term follow up has shown us an improved safety profile of acalabrutinib monotherapy. With an impressive median duration of response (DOR) of 28.6 months, a median progression-free survival (PFS) of 22 months and an estimated 36-month overall survival rate of 61%, acalabrutinib certainly has potential as a novel treatment in R/R MCL patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.


Dr Michael Wang has received grants from Pharmacyclics, Celgene, Janssen, AstraZeneca/Acerta, Juno, Loxo Oncology, VelosBio, BioInvent, Kite Pharma, Verastem, BeiGene, Eli Lilly, InnoCare and Molecular Templates; has received personal fees from Pharmacyclics, Celgene, Janssen, AstraZeneca/Acerta, OMI, Pulse Biosciences, Juno, Loxo Oncology, VelosBio, Targeted Oncology, Kite Pharma, Guidepoint Global, BeiGene, InnoCare and Oncternal; has received non-financial support from Pharmacyclics, Celgene, Janssen and OMI.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter